Volume 24, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



In a controlled field trial of treatment for dracontiasis, mebendazole (Vermox®) was found to be effective in eliminating the adult worm and preventing clinical relapses, but it did not achieve significant amelioration of symptoms, subsidence of inflammation, or healing of ulcers. The failure is attributed to poor absorption and lack of anti-inflammatory action of the drug. Mebendazole was well tolerated and although two patients reported mild gastro-intestinal disturbances, which may be attributed to the drug, the study confirms that mebendazole is one of the safest anthelmintics in current use and is in that respect ideal for mass therapy.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error